Company intelligence / Profile preview
Recida Therapeutics
Menlo Park, California, United Statesrecidatherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Recida Therapeutics is developing RC-01, an IND-stage LpxC inhibitor with broad-spectrum bactericidal activity against major multidrug-resistant gram-negative pathogens. Preclinical data show favorable pharmacokinetics and safety. The company has received funding from CARB-X to advance this program into clinical development
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules (specifically LpxC inhibitors)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
CARB-X funding partnership for antibiotic development
Beyond the preview
Go deeper on Recida Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Recida Therapeutics.